Evidence map›Paper›PMID 36071789›Full record

ArticleJournal of thoracic disease2022

Diagnosis and prognosis of acute respiratory distress syndrome related to diffuse pneumonic-type adenocarcinoma: a single-center case series study.

Maxens Decavèle, Antoine Parrot, Michaël Duruisseaux, Martine Antoine, Anne Fajac, Audrey Milon, Marie-France Carette, Anthony Canellas, Aude Gibelin, Alexandre Elabbadi and 3 more

Open access · diamondAbstract read
In one paragraph

Article in Journal of thoracic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Maxens DecavèleGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.
Antoine ParrotGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique and GRC-04 Theranoscan Sorbonne Université, Paris, France.
Michaël DuruisseauxDepartment of Respiratory Medicine, Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, France.
Martine AntoineGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Département d'Anatomie et cytologie pathologiques, Plateforme d'oncologie, Pathologie et biologie moléculaire, Paris, France.
Anne FajacGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Département d'Anatomie et cytologie pathologiques, Plateforme d'oncologie, Pathologie et biologie moléculaire, Paris, France.
Audrey MilonGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon Service de Radiologie, Hôpital Tenon, Paris, France.
Marie-France CaretteGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon Service de Radiologie, Hôpital Tenon, Paris, France.
Anthony CanellasGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique and GRC-04 Theranoscan Sorbonne Université, Paris, France.
Aude GibelinGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.
Alexandre ElabbadiGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.
Marie WislezUniversité de Paris, Centre de Recherche des Cordeliers, Sorbonne Université, INSERM, Team Inflammation, Complement, and Cancer, Paris, France.
Jacques CadranelGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Pneumologie et Oncologie Thoracique and GRC-04 Theranoscan Sorbonne Université, Paris, France.
Muriel FartoukhGroupe Hospitalier Universitaire APHP-Sorbonne Université, Hôpital Tenon, Service de Médecine Intensive Réanimation, Paris, France.
Hôpital Tenon · FRSorbonne Université · FRAssistance Publique – Hôpitaux de Paris · FRTHERANOSCAN : Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites CellulesHospices Civils de Lyon · FRInserm · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The absence of diagnosis of acute respiratory distress syndrome (ARDS) concerns 20% of cancer patients and is associated with poorer outcomes. Diffuse pneumonic-type adenocarcinoma (P-ADC) is part of these difficult-to-diagnose ARDS, but only limited data are available regarding critically ill patients with diffuse P-ADC. We sought to describe the diagnosis process and the prognosis of P-ADC related ARDS patients admitted to the intensive care unit (ICU). Methods: Single-center observational case series study. All consecutive patients admitted to the ICU over a two-decade period presenting with (I) histologically or cytologically proven adenocarcinoma of the lung and (II) ARDS according to Berlin definition were included. Clinical, biological, radiological and cytological features of P-ADC were collected to identify diagnostic clues. Multivariate logistic regression analyses were performed to assess factors associated with ICU and hospital mortality. Results: Among the 24 patients included [70 (61-75) years old, 17 (71%) males], the cancer diagnosis was performed during the ICU stay in 19 (79%), and 17 (71%) required mechanical ventilation. The time between the first symptoms and the diagnosis of P-ADC was 210 days (92-246 days). A non-resolving pneumonia after 2 (2 to 3) antibiotics lines observed in 23 (96%) patients with a 34 mg/L (19 to 75 mg/L) plasma C-reactive protein level at ICU admission. Progressive dyspnea, bronchorrhea, salty expectoration, fissural bulging and compressed bronchi and vessels were present in 100%, 83%, 69%, 57% and 43% of cases. Cytological examination of sputum or broncho-alveolar lavage provided a 75% diagnostic yield. The ICU and hospital mortality rates were 25% and 63%, respectively. The time (in days) between first symptoms and diagnosis [odds ratio (OR) 1.02, 95% confidence interval (95% CI): 1.00-1.03, P=0.046] and the Simplified Acute Physiology Score II (OR 1.16, 95% CI: 1.01-1.33, P=0.040) were independently associated with ICU mortality. Conclusions: Non-resolving pneumonia after several antibiotics lines without inflammatory syndrome, associated with progressive dyspnea, salty bronchorrhea, and lobar swelling (i.e., fissural bulging, compressed bronchi and vessels) were suggestive of P-ADC. Delayed diagnosis of diffuse P-ADC seemed an independent prognostic predictor and disease timely recognition may contribute to prognosis improvement.

Indexed as

acute respiratory distress syndrome (ARDS)broncho-alveolar carcinomaIntensive care unit (ICU)lung cancerpneumonic-type adenocarcinoma (P-ADC)

Identifiers

PMID36071789
PMCPMC9442528
OpenAlexW4285120816

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.